MCRN 004 – The LAURENTIANS Trial
Daratumumab (Darzalex®) is the first monoclonal antibody for the treatment of myeloma to be approved by Health Canada. Although daratumumab was approved by Health Canada on April 17, 2017, it is not yet covered by any of the provincial drug plans. For many patients in need, a clinical trial is one of the ways to access this treatment. LAURENTIANS will not only provide access to daratumumab for eligible patients across the country, but it will also answer the question of how to optimize the use of expensive drugs using a cost-effective approach.
Led by Dr Michael Sebag at the McGill University Health Centre in Montreal, this open-label trial is planned to recruit a total of 120 patients across Canada into two study arms. One group will receive daratumumab, cyclophosphamide, dexamethasone and pomalidomide (Pomalyst®). The other group will receive the same treatment regimen, however pomalidomide will only be added when the participant’s disease progresses.
The trial was activated on October 25, 2017 and the following centres are open for recruitment:
- Calgary – Tom Baker Cancer Centre
- Edmonton – Cross Cancer Institute
- Halifax – Queen Elizabeth II Health Sciences Centre
- Hamilton – Juravinski Cancer Centre
- Ottawa – Ottawa General Hospital
- Saint John – Saint John Regional Hospital
- Saskatoon – Saskatoon Cancer Centre
- Surrey – BCCA Fraser Valley Centre
- Thunder Bay – Thunder Bay Regional HSC
- Toronto – Princess Margret Cancer Centre
- Winnipeg – CancerCare Manitoba